Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SAMD12 antisense RNA 1 (SAMD12-AS1)
- Target
- SAMD12-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
SAMD12 antisense RNA 1 (SAMD12-AS1) is a long non-coding RNA (lncRNA) located on chromosome 8, transcribed antisense to the SAMD12 gene. It is not translated into protein and acts as a regulatory RNA molecule in human cells. SAMD12-AS1 is upregulated in various tumor tissues, including liver and gastric cancers, as well as in neuroblastoma. Its expression is further enhanced by hepatitis B virus (HBV) infection through the viral HBx protein. SAMD12-AS1 promotes cancer cell proliferation and inhibits apoptosis primarily by interacting with nucleophosmin (NPM1), which affects the NPM1-HDM2-p53 pathway, resulting in reduced p53 protein stability and function. This activity contributes to tumorigenesis and malignant transformation by allowing cells to evade p53-mediated cell cycle arrest and apoptosis. SAMD12-AS1 is considered of interest both as a potential therapeutic target and as a biomarker for prognosis in p53-related cancers.
- Other names
- C8orf26NCRNA00252
02
Mechanism of action
Regulates cell growth and apoptosis by interacting with NPM1, facilitating HDM2-mediated p53 ubiquitination and degradation, thus reducing p53 tumor suppressor stability
03
Biological functions
Regulation of cell proliferationInhibition of apoptosisPost-transcriptional regulation of gene expressionInteraction with nucleophosmin (NPM1) and modulation of the NPM1-HDM2-p53 axis
04
Disease associations
Cancer (notably hepatocellular carcinoma, gastric cancer, neuroblastoma)Potential role in genetic diseases related to disrupted cell proliferation
05
Biomarkers
Potential prognostic biomarker for hepatocellular carcinoma and other cancers associated with altered p53 signaling
Beyond the preview
Go deeper on SAMD12 antisense RNA 1 (SAMD12-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAMD12 antisense RNA 1 (SAMD12-AS1).